Dozens of Maryland Companies Take Active Role in Developing Coronavirus Treatment

covid_coronavirus-4970581_1920_05-21-2020_Pixabay_VWNearly 40 Maryland based life sciences companies and research hospitals have dedicated time and resources to provide COVID-19 therapeutic or technological support including to help develop and manufacture vaccines. 

These institutions include the University System of Maryland and Johns Hopkins University. Each of which has dedicated millions towards comprehensive COVID-19 research and treatment. The former’s School of Medicine has begun phase 3 trials of a COVID-19 vaccine.

A press release from the Governor’s Office highlights the contributions Maryland companies have made towards coronavirus response.

To date, Maryland’s life sciences companies have secured more than $3 billion for the development of a vaccine for SARS-CoV-2, the virus that causes COVID-19.

  • Gaithersburg-based Novavax was awarded $1.6 billion through Operation Warp Speed to complete late-stage clinical development, establish large-scale manufacturing, and deliver 100 million vaccine doses as early as late 2020, as well as $388 million from the international Coalition for Epidemic Preparedness Innovations and $60 million through a U.S. Department of Defense contract to support vaccine production.
  • Emergent BioSolutions, with its headquarters and product development facility also based in Gaithersburg and three manufacturing facilities in Baltimore and Rockville, announced it signed contracts with AstraZeneca, Johnson & Johnson, Novavax, and Vaxart as well as with Operation Warp Speed for a total of $1.5 billion to support COVID-19 vaccine candidate development and manufacturing.
  • Bethesda-based Longhorn Vaccines and Diagnostics won a $225 million U.S. Department of Homeland Security contract to transport clinical samples to testing labs.
  • Altimmune, headquartered in Gaithersburg, was awarded a $4.7 million contract from the U.S. Army Medical Research and Development Command and is working with Rockville-based Vigene Biosciences on the development of a single-dose intranasal COVID-19 vaccine.

For more information:

Nearly 40 Maryland Companies, Universities Working on Vaccines, Therapeutics, Diagnostic Tests, and Clinical Research (press release)